Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction

Resuscitation

Volumn 81, Issue 6, 2010, Pages 755-760

  Dokken, Betsy B ^a,b   Hilwig, W Ronald ^a   Teachey, Mary K ^a   Panchal, R Ashish ^a,b   Hubner, Karl ^b   Allen, Daniel ^b   Rogers, David C ^b   Kern, Karl B ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Coronary flow reserve; GLP 1; Microcirculation; Resuscitation

Indexed keywords

ADENOSINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LACTIC ACID; PLACEBO; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCULATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY FLOW RESERVE; DEFIBRILLATION; DOPPLER FLOWMETRY; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BLOOD FLOW; HEART OUTPUT; HEART VENTRICLE FIBRILLATION; MICROCIRCULATION; MYOCARDIAL DISEASE; NERVOUS SYSTEM FUNCTION; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; SCORING SYSTEM; SURVIVAL RATE; SWINE; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CARDIAC OUTPUT; CARDIOPULMONARY RESUSCITATION; CORONARY CIRCULATION; CORONARY DISEASE; GLUCAGON-LIKE PEPTIDE 1; HEART; HEMODYNAMICS; HUMANS; INFUSION PUMPS; INSULIN; LACTIC ACID; MICROCIRCULATION; NERVOUS SYSTEM; OSMOLAR CONCENTRATION; SURVIVAL RATE; SWINE; TIME FACTORS; VENTRICULAR FIBRILLATION;

EID: 77952889531     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2010.01.031     Document Type: Article

References (61)

1. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. N Engl J Med 1986, 314:397-403.
2. Abramson N.S. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac-arrest. N Engl J Med 1991, 324:1225-1231.
3. Schoenenberger R.A., von Planta M., von Planta I. Survival after failed out-of-hospital resuscitation: are further therapeutic efforts in the emergency department futile? Arch Intern Med 1994, 154:2433-2437.
4. Kern K.B., Zuercher M., Cragun D., et al. Myocardial microcirculatory dysfunction after prolonged ventricular fibrillation and resuscitation. Crit Care Med 2008, 36:S418-S421.
5. Kern K., Hilwig R., Rhee K., Berg R. Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. J Am Coll Cardiol 1996, 28:232-240.
6. Celik T., Iyisoy A., Kardesoglu E., Isik E. The clinical significance of microvascular impairment in patients with pure uncomplicated diabetes mellitus. Int J Cardiol 2008, 131:123-124.
7. Jones C.J.H., Kuo L., Davis M.J., Chilian W.M. Myogenic and flow-dependent control mechanisms in the coronary microcirculation. Basic Res Cardiol 1993, 88:2-10.
8. Fischer M., Hossmann K.-A. Volume expansion during cardiopulmonary resuscitation reduces cerebral no-reflow. Resuscitation 1996, 32:227-240.
9. Fries M., Weil M.H., Chang Y.T., Castillo C., Tang W.C. Microcirculation during cardiac arrest and resuscitation. Crit Care Med 2006, 34:S454-S457.
10. Berg R.A., Sanders A.B., Kern K.B., et al. Adverse hemodynamic effects of interrupting chest compressions for rescue breathing during cardiopulmonary resuscitation for ventricular fibrillation cardiac arrest. Circulation 2001, 104:2465-2470.
11. Gudipati C.V., Weil M.H., Bisera J., Deshmukh H.G., Rackow E.C. Expired carbon-dioxide-a noninvasive monitor of cardiopulmonary resuscitation. Circulation 1988, 77:234-239.
12. Paradis N.A., Martin G.B., Rivers E.P., et al. Coronary perfusion-pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990, 263:1106-1113.
13. Sato Y., Weil M.H., Sun S.J., et al. Adverse effects of interrupting precordial compression during cardiopulmonary resuscitation. Crit Care Med 1997, 25:733-736.
14. Kern M.J. Coronary physiology revisited-practical insights from the cardiac catheterization laboratory. Circulation 2000, 101:1344-1351.
15. Kern M.J., deBruyne B., Pijls N.H.J. From research to clinical practice: current role of intracoronary physiologically based decision making in the cardiac catheterization laboratory. J Am Coll Cardiol 1997, 30:613-620.
16. Klocke F. Measurements of coronary flow reserve: defining pathophysiology versus making decisions about patient care. Circulation 1987, 76:1183-1189.
17. Bache R.J. Vasodilator reserve-a functional assessment of coronary health. Circulation 1998, 98:1257-1260.
18. Strauer B.E. The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol 1990, 15:775-783.
19. Brush J.E., Cannon R.O., Schenke W.H., et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988, 319:1302-1307.
20. Mafong D., Henry R. The role of incretins in cardiovascular control. Curr Hypertens Rep 2009, 11:18-22.
21. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
22. Bose A.K., Mocanu M.M., Carr R.D., Yellon D.M. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007, 21:253-256.
23. Dokken BB, Labonte LR, Davis-Gorman G, McDonagh PF. Postconditioning with GLP-1 in vivo decreases myocardial infarct size in rats: Diabetes 2007;56:A15-A16. Abstract.
24. Dokken B.B., La Bonte L.R., Davis-Gorman G., McDonagh P.F. Treatment with glucagon-like peptide-1 during reperfusion decreases ischemia-reperfusion injury in type 2 diabetic rat hearts. FASEB J. 2008, 22. 1130.1114-.
25. Nikolaidis L.A., Elahi D., Hentosz T., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
26. Timmers L., Henriques J.P.S., de Kleijn D.P.V., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510.
27. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
28. Gros R., You X.M., Baggio L.L., et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144:2242-2252.
29. Green B.D., Hand K.V., Dougan J.E., McDonnell B.M., Cassidy R.S., Grieve D.J. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving K-ATP and cAMP. Arch Biochem Biophys 2008, 478:136-142.
30. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
31. Kern K.B., Hilwig R.W., Rhee K.H., Berg R.A. Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. J Am Coll Cardiol 1996, 28:232-240.
32. Raya T.E., Gay R.G., Lancaster L., Aguirre M., Moffett C., Goldman S. Serial changes in left-ventricular relaxation and chamber stiffness after large myocardial infarction in rats. Circulation 1988, 77:1424-1431.
33. Gould K., Kirkeeide R., Buchi M. Coronary flow reserve as a physiologic measure of stenosis severity. J Am Coll Cardiol 1990, 15:459-474.
34. Marcus M., Wright C., Doty D., et al. Measurements of coronary velocity and reactive hyperemia in the coronary circulation of humans. Circ Res 1981, 49:877-891.
35. Hoffman J. Maximal coronary flow and the concept of coronary vascular reserve. Circulation 1984, 70:153-159.
36. DeFily D.V., Chilian W.M. Coronary microcirculation: autoregulation and metabolic control. Basic Res Cardiol 1995, 90:112-118.
37. Komaru T., Lamping K.G., Dellsperger K.C. Role of adenosine in vasodilation of epimyocardial coronary microvessels during reduction in perfusion pressure. J Cardiovasc Pharmacol 1994, 24:434-442.
38. Schnaar R., Sparks H. Response of large and small coronary arteries to nitroglycerin, NaNO2, and adenosine. Am J Physiol 1972, 223:223-228.
39. Nevo E., Nevo S., Beyar R. The physiologic meaning of relative coronary flow reserve. Am J Cardiol 1995, 75:285-287.
40. Nystrom T., Gutniak M.K., Zhang Q., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-1215.
41. Basu A., Charkoudian N., Schrage W., Rizza R.A., Basu R., Joyner M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007, 293:E1289-E1295.
42. Kern K.B., Zuercher M., Cragun D., et al. Myocardial microcirculatory dysfunction after prolonged ventricular fibrillation and resuscitation. Critical care medicine ninth wolf creek conference on CPR: addressing the scientific basis of reanimation, vol. 36 2008, S418-S421.
43. Ambrosio G., Weisman H., Mannisi J., Becker L. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989, 80:1846-1861.
44. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
45. Huisamen B., Genade S., Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr 2008, 19:77-83.
46. Kavianipour M., Ehlers M.R., Malmberg K., et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003, 24:569-578.
47. Apstein C., Gravino F., Haudenschild C. Determinants of a protective effect of glucose and insulin on the ischemic myocardium. Effects on contractile function, diastolic compliance, metabolism, and ultrastructure during ischemia and reperfusion. Circ Res 1983, 52:515-526.
48. Malhotra R., Brosius F.C. Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. J Biol Chem 1999, 274:12567-12575.
49. Villanueva-Peñacarrillo M.L., Alcántara A.I., Clemente F., Delgado E., Valverde I. Potent glycogenic effect of GLP-1 (7-36) amide in rat skeletal muscle. Diabetologia 1994, 37:1163-1166.
50. Shulman G., Rothman D., Jue T., Stein P., DeFronzo R., Shulman R. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990, 322:223-228.
51. Zhao T.C., Parikh P., Bhashyam S., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-1113.
52. Cabrera M.E., Zhou L., Stanley W.C., Saidel G.M. Regulation of cardiac energetics: role of redox state and cellular compartmentation during ischemia. Ann N Y Acad Sci 2005, 1047:259-270.
53. Lehninger A.L., Cox M.M., Nelson D.L. Lehninger principles of biochemistry 2005, W.H. Freeman, New York.
54. James J.H., Luchette F.A., McCarter F.D., Fischer J.E. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. The Lancet 1999, 354:505-508.
55. Cheatham B., Kahn C.R. Insulin action and the insulin signaling network. Endocr Rev 1995, 16:117-142.
56. Hwang D.-Y., Ismail-Beigi F. Glucose uptake and lactate production in cells exposed to CoCl2 and in cells overexpressing the Glut-1 glucose transporter. Arch Biochem Biophys 2002, 399:206-211.
57. Liao R., Jain M., Cui L., et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 2002, 106:2125-2131.
58. Fralix T.A., Steenbergen C., London R.E., Murphy E. Metabolic substrates can alter postischemic recovery in preconditioned ischemic heart. Am J Physiol Cell Physiol 1992, 263:C17-23.
59. Goodwin G.W., Taegtmeyer H. Metabolic recovery of isolated working rat heart after brief global ischemia. Am J Physiol Heart Circ Physiol 1994, 267:H462-H470.
60. Lloyd S., Brocks C., Chatham J.C. Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart. Am J Physiol Heart Circ Physiol 2003, 285:H163-H172.
61. Davies M., Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984, 310:1137-1140.